Study objectives: The pathophysiologic role of nitric oxide (NO) released in the lung is not well understood. To determine whether the production of endogenous NO is correlated with any hemodynamic parameters, we measured the amount of NO released from the lung tissue of patients with heart disease.
Several studies have shown that the vasodilatory response or the blood flow response to acetylcholine is blunted in the peripheral resistance vessels in suminoh@news.sb.gunma-u.ac.jp heart failure, indicating an impairment in receptormediated NO release from the endothelium. [3] [4] [5] [6] [7] contrast, the peripheral vasoconstrictor response to NG-monomethyl-L-arginine (L-NMMA), an inhibi¬ tor of NO synthesis, is exaggerated, suggesting that the basal release of NO from the endothelium of resistance vessels is enhanced. 4 The pulmonary vasoconstricting response to L-NMMA has been stud¬ ied in both normal humans and patients with heart failure. 810 The results suggested that the basal re¬ lease of NO from pulmonary vessels is also exagger¬ ated in the patients. Thus, it is still not clear whether NO release from systemic and pulmonary vascular endothelia is enhanced or inhibited in heart failure.
To clarify the actual contribution of NO to the vascular tone in heart failure, a direct estimation of NO (6) , furosemide (6) , and digoxin (4) . None (Fig 1) . The rate of NO release in the patients with heart disease was positively corre¬ lated with the cardiac index (r=0.50, p<0.05) (Fig  2) , and was negatively correlated with the systemic vascular resistance (r=.0.58, p<0.01) and pulmo¬ nary vascular resistance (r=.0.45, p<0.05) (Fig 3) .
The patients with heart disease were subdivided into two groups, according to severity: a mild heart failure group and a moderate-to-severe heart failure group ( Table 1) . The moderate-to-severe heart fail- 
